Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy
AbstractImmune checkpoint inhibitor therapy (ICT) is a new treatment strategy developed for the treatment of cancer. ICT inhibits pathways known to downregulate the innate immune response to cancer cells. These drugs have been shown to be effective in the treatment of a variety of cancers, including metastatic melanoma and lung cancer. Challenges in response evaluation of patients in ICT have risen as immune related side effects and immune cell infiltration may be confused with progressive disease. Furthermore, the timing of the evaluation scan may be challenged by relatively slow responses. To overcome this, new response criteria for evaluating these patients with morphologic imaging have been proposed. The aim of this paper is to review and discuss the current evidence for the use of molecular imaging, e.g., PET/CT (Positron Emission Tomography/Computer Tomography) with 18F-Fluorodeoxyglucoes (FDG) as an alternative imaging method for monitoring patients undergoing ICT. Following the currently available evidence, this review will primarily focus on patients with malignant melanoma. View Full-Text
Share & Cite This Article
Guldbrandsen, K.F.; Hendel, H.W.; Langer, S.W.; Fischer, B.M. Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. Diagnostics 2017, 7, 23.
Guldbrandsen KF, Hendel HW, Langer SW, Fischer BM. Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. Diagnostics. 2017; 7(2):23.Chicago/Turabian Style
Guldbrandsen, Kasper F.; Hendel, Helle W.; Langer, Seppo W.; Fischer, Barbara M. 2017. "Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy." Diagnostics 7, no. 2: 23.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.